Abstract
Background: In recent years, there have been reports of contact dermatitis due to the beta-blockers that are used in the treatment of glaucoma, such as timolol, levubonolol, carteolol, or betaxolol.
Case report: A 37-year-old male patient, who was diagnosed with bilateral primary open-angle glaucoma two years ago, was in therapy with dorzolamide and a topical β-adrenergic blocker (timolol) in drops twice a day. Months later, he reported conjunctival hyperemia, stinging, and inflammation of both eyelids, followed by erythematous dermatitis, which improved upon treatment discontinuation. The patch test came back negative, but the conjunctival provocation test came back positive 48 hours later.
Conclusion: Sensitization to the ophthalmic drops that are used to control glaucoma proved to be the mechanism that was causing the clinical picture of the patient. Performing a tolerance test for active anti-glaucoma agents may be helpful in improving tolerance to the medical treatment of some patients, thus, avoiding laser procedures and / or precipitated antiglaucomatous surgeries.
References
Tham YC, LiX, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and metanalysis. Ophthalmology. 2014;121(11):2081-2090. DOI: 10.1016/j.ophtha.2014.05.013
Blanco E, de Santiago F. Glaucoma crónico. Tendencias en Medicina. 2019;14:113-117.
Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262-267. DOI: 10.1136/bjo.2005.081224
Reyna M, Consigli CA. Blefaroconjuntivitis de contacto alérgica por timolol. Arch Argent Dermatol. 2002;52(5):213-215.
Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol. 2008;86(7):716- 726. DOI: 10.1111/j.1755-3768.2008.01250.x
O’Donnell BF, Foulds S. Contact allergy to beta blocking agents in ophtalmic preparations. Contact Dermatitis. 1993;28:121-122. DOI: 10.1111/j.1600-0536.1993.tb03364.x
García F, Blanco J, Juste S, Garcés MM, Alonso L, Marcos ML. Contact dermatitis due to levobunolol in eyedrops. Contact Dermatitis. 1997;36(4):230. DOI: 10.1111/j.1600-0536.1997.tb00280.x
Quiralte J, Florido F, Sáenz-De San Pedro B. Allergic contact dermatitis from carteolol and timolol in eyedrops. Contact Derm. 2000;42(4):245.
Holdiness MR. Contact dermatitis to topical drugs for glaucoma. Am J Contact Dermat. 2001;12(4):217-219. DOI: 10.1053/ajcd.2001.25129
Schuman JS. Clinical experience with brimonidine 0,2 % and timolol 0,5 % in glaucoma and ocular hypertension. Surv Ophthalmol. 1996;41:827-837. DOI: 10.1016/s0039-6257(96)82029-7
Statham BN. Failure of patch testing with levobunolol eyedrops to detect contact allergy. Contact Derm. 2000;43:365-366.
Grey KR, Warshow EM. Allergic contact dermatitis to ophthalmic medications: relevant allergens an alternative testing methods. Dermatitis. 2016;27(6):333-347. DOI: 10.1097/DER.0000000000000224
Jappe U, Uter W, Menezes-De Pádua CA, Herbst RA, Schnuch A. Allergic contact dermatitis due to ßblockers in eye drops: a retrospective analysis of multicentre surveillance data 1993-2004. Acta Derm Venereol. 2006;86(6):509-514. DOI: 10.2340/00015555-0162
Horcajada-Reales C, Rodríguez-Soria VJ, Suárez- Fernández R. Allergic contact dermatitis caused by timolol with cross-sesitivity to levobunolol. Contact Dermatitis. 2015;73(6):368-369. DOI: 10.1111/cod.12448
Gilissen L, de Decker L, Hulshagen T, Goossens A. Allergic contact dermatitis caused by topical ophthalmic medications: keep an eye on it. Contac Dermatitis. 2019;80(5):291-297. DOI: 10.1111/cod.13209
Abreu JA, Blasco A, Arteaga, Abreu R. Dermatitis de contacto alérgica palpebral bilateral debida a timolol. Arch Soc Canar Oftal. 2019;30:83-86. Disponible en: http://sociedadcanariadeoftalmologia.com/wp-content/revista/revista-30/30sco15.pdf
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2020 Revista Alergia México